Teratogenic mechanisms of medical drugs

Human Reproduction Update

Volumn 16, Issue 4, 2010, Pages 378-394

  van Gelder, Marleen M H J ^a   van Rooij, Iris A L M ^a   Miller, Richard K ^b   Zielhuis, Gerhard A ^a   de Jong van den Berg, Lolkje T W ^c   Roeleveld, Nel ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Congenital abnormalities; Pharmaceutical agents; Pregnancy; Teratology

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANGIOTENSIN RECEPTOR; CARBONATE DEHYDRATASE; CYCLOOXYGENASE 1; DIPEPTIDYL CARBOXYPEPTIDASE; FOLIC ACID; FOLIC ACID ANTAGONIST; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEX HORMONE; TERATOGENIC AGENT;

BIRTH DEFECT; CELL DISRUPTION; DATA BASE; DRUG MARKETING; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; NEURAL CREST CELL; NONHUMAN; OXIDATIVE STRESS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TERATOGENESIS; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ENDOCRINE DISRUPTORS; ENZYME INHIBITORS; FEMALE; FETUS; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; MICE; NEURAL CREST; OXIDATIVE STRESS; PLACENTAL CIRCULATION; PREGNANCY; PRESCRIPTION DRUGS; RATS;

EID: 77953361825     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmp052     Document Type: Review

References (255)

1. Adham IM, Agoulnik AI. Insulin-like 3 signalling in testicular descent. Int J Androl 2004;27:257-265.
2. Åkesson E, Kjældgaard A, Samuelsson EB, Seiger A, Sundström E. Ionotropic glutamate receptor expression in human spinal cord during first trimester development. Brain Res Dev Brain Res 2000;119:55-63.
3. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-2692.
4. Andaloro VJ, Monaghan DT, Rosenquist TH. Dextromethorphan and other N-methyl-D-aspartate receptor antagonists are teratogenic in the avian embryo model. Pediatr Res 1998;43:1-7.
5. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79:565-575.
6. Antony AC. The biological chemistry of folate receptors. Blood 1992; 79:2807-2820.
7. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151-156.
8. Bakker MK, Jentink J, Vroom F, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006;113:559-568.
9. Bennett GD, VanWaes J, Moser K, Chaudoin T, Starr L, Rosenquist TH. Failure of homocysteine to induce neural tube defects in a mouse model. Birth Defects Res B Dev Reprod Toxicol 2006;77:89-94.
10. Bérard A, Ramos E, Rey E, Blais L, St André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80:18-27.
11. Blom HJ, Shaw GM, den Heijer M, Finnell RH. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 2006;7:724-731.
12. Blower PR. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 2003;11:93-100.
13. Bockman DE, Kirby ML. Dependence of thymus development on derivatives of the neural crest. Science 1984;223:498-500.
14. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862-877.
15. Briggs GG, Freeman RK, Yaffe SJ. Dextromethorphan. In Briggs GG, Freeman RK, Yaffe SJ (eds). Drugs in Pregnancy and Lactation. Philadelphia: Lippincott, Williams & Wilkins, 2008, 506-510.
16. Brouwer IA, van Dusseldorp M, West CE, Meyboom S, Thomas CMG, Duran M, van het Hof KH, Eskes TKAB, Hautvast JGAJ, Steegers-Theunissen RPM. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. J Nutr 1999;129:1135-1139.
17. Brouwers MM, Feitz WFJ, Roelofs LAJ, Kiemeney LALM, de Gier RPE, Roeleveld N. Hypospadias: a transgenerational effect of diethylstilbestrol? Hum Reprod 2006;21:666-669.
18. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004;23:6693-6701.
19. Candito M, Rivet R, Herbeth B, Boisson C, Rudigoz RC, Luton D, Journel H, Oury JF, Roux F, Saura R et al. Nutritional and genetic determinants of vitamin B and homocysteine metabolisms in neural tube defects: a multicenter case-control study. Am J Med Genet A 2008;146:1128-1133.
20. Cappon GD, Cook JC, Hurtt ME. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol 2003; 68:47-56.
21. Carr BR, Parker CR Jr, Milewich L, Porter JC, MacDonald PC, Simpson ER. The role of low density, high density, and very low density lipoproteins in steroidogenesis by the human fetal adrenal gland. Endocrinology 1980; 106:1854-1860.
22. Cederroth CR, Schaad O, Descombes P, Chambon P, Vassalli JD, Nef S. Estrogen receptor a is a major contributor to estrogen-mediated fetal testis dysgenesis and cryptorchidism. Endocrinology 2007; 148:5507-5519.
23. Chai Y, Maxson RE Jr. Recent advances in craniofacial morphogenesis. Dev Dynam 2006;235:2353-2375.
24. Choi DS, Ward SJ, Messaddeq N, Launay JM, Maroteaux L. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development 1997;124:1745-1755.
25. Christiansen S, Scholze M, Axelstad M, Boberg J, Kortenkamp A, Hass U. Combined exposure to anti-androgens causes markedly increased frequencies of hypospadias in the rat. Int J Androl 2008;31:241-248.
26. Clarren SK, Alvord EC Jr, Sumi SM, Streissguth AP, Smith DW. Brain malformations related to prenatal exposure to ethanol. J Pediatr 1978; 92:64-67.
27. Cleves MA, Savell VH Jr, Raj S, Zhao W, Correa A, Werler MM, Hobbs CA. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res A Clin Mol Teratol 2004;70:107-113.
28. Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, Kumada M, Hammer RE, Yanagisawa M. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 1998;125:813-824.
29. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-235.
30. Coelho CND, Klein NW. Methionine and neural tube closure in cultured rat embryos: morphological and biochemical analyses. Teratology 1990; 42:437-451.
31. Cook JC, Jacobson CF, Gao F, Tassinari MS, Hurtt ME, DeSesso JM. Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2003;68:5-26.
32. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443-2451.
33. Cragan JD, Martin ML, Waters GD, Khoury MJ. Increased risk of small intestinal atresia among twins in the United States. Arch Pediatr Adolesc Med 1994;148:733-739.
34. Crescioli C, Maggi M, Vannelli GB, Ferruzzi P, Granchi S, Mancina R, Muratori M, Forti G, Serio M, Luconi M. Expression of functional estrogen receptors in human fetal male external genitalia. J Clin Endocrinol Metab 2003;88:1815-1824.
35. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. Br Med J 1993;306:1645-1648.
36. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicol Teratol 2004;26:593-598.
37. Danielsson BR, Sköld AC, Johansson A, Dillner B, Blomgren B. Teratogenicity by theh ERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 2003;193:168-176.
38. Defoort EN, Kim PM, Winn LM. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 2006;69:1304-1310.
39. Delbès G, Levacher C, Duquenne C, Racine C, Pakarinen P, Habert R. Endogenous estrogens inhibit mouse fetal Leydig cell development via estrogen receptor a. Endocrinology 2005;146:2454-2461.
40. Dennery PA. Effects of oxidative stress on embryonic development. Birth Defects Res C Embryo Today 2007;81:155-162.
41. Di Renzo F, Cappelletti G, Broccia ML, Giavini E, Menegola E. Boric acid inhibits embryonic histone deacetylases: a suggested mechanism to explain boric acid-related teratogenicity. Toxicol Appl Pharmacol 2007; 220:178-185.
42. Di Renzo F, Cappelletti G, Broccia ML, Giavini E, Menegola E. The inhibition of embryonic histone deacetylases as the possible mechanism accounting for axial skeletal malformations induced by sodium salicylate. Toxicol Sci 2008;104:397-404.
43. Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, Koren G. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23-28.
44. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008; 66:695-705.
45. Dobbing J, Sands J. Vulnerability of developing brain. IX. The effect of nutritional growth retardation on the timing of the brain growth-spurt. Biol Neonate 1971;19:363-378.
46. Dobbing J, Sands J. Quantitative growth and development of human brain. Arch Dis Child 1973;48:757-767.
47. Dolovich LR, Addis A, Vaillancourt JMR, Power JDB, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. Br Med J 1998;317:839-843.
48. Duester G. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem 2000;267:4315-4324.
49. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004;131:287-298.
50. Eikel D, Lampen A, Nau H. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 2006; 19:272-278.
51. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, Kennedy D, Einarson TR, Koren G. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165:749-752.
52. Elberger AJ, Deng J. Corpus callosum and visual cortex of mice with deletion of the NMDA-NR1 receptor: I. Accelerated development of callosal projection neurons. Brain Res Dev Brain Res 2003; 144:121-133.
53. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990;30:1-45.
54. Elmazar MMA, Rühl R, Reichert U, Shroot B, Nau H. RARa-mediated teratogenicity in mice is potentiated by an RXR agonist and reduced by an RAR antagonist: dissection of retinoid receptor-induced pathways. Toxicol Appl Pharmacol 1997;146:21-28.
55. Emmen JMA, McLuskey A, Adham IM, Engel W, Verhoef-Post M, Themmen APN, Grootegoed JA, Brinkmann AO. Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology 2000;141:846-849.
56. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106 000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008;65:653-660.
57. Epstein JA, Li J, Lang D, Chen F, Brown CB, Jin F, Lu MM, Thomas M, Liu ECJ, Wessels A et al. Migration of cardiac neural crest cells in Splotch embryos. Development 2000;127:1869-1878.
58. Erdö SL, Joo F, Wolff JR. Immunohistochemical localization of glutamate decarboxylase in the rat oviduct and ovary: further evidence for non-neural GABA systems. Cell Tissue Res 1989;255:431-434.
59. Ericson A, Källén BAJ. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371-375.
60. Fantel AG, Person RE. Involvement of mitochondria and other free radical sources in normal and abnormal fetal development. Ann N Y Acad Sci 2002;959:424-433.
61. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 Perspect Sex. Reprod Health 2006; 38:90-96.
62. Foster W, Myllynen P, Winn LM, Ornoy A, Miller RK. Reactive oxygen species, diabetes and toxicity in the placenta: a workshop report. Placenta 2008;29:S105-S107.
63. Fujii H, Sato T, Kaneko S, Gotoh O, Fujii-Kuriyama Y, Osawa K, Kato S, Hamada H. Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. EMBO J 1997; 16:4163-4173.
64. Gaskell TL, Robinson LLL, Groome NP, Anderson RA, Saunders PTK. Differential expression of two estrogen receptor b isoforms in the human fetal testis during the second trimester of pregnancy. J Clin Endocrinol Metab 2003;88:424-432.
65. Gilbert-Barness E, Van Allen MI. Vascular disruptions. In Gilbert-Barness E, Kapur RP, Siebert JR, Potter EL (eds). Potter's Pathology of the Fetus, Infant and Child. Philadelphia, PA: Mosby Elsevier, 2007, 176-212.
66. Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541-1545.
67. Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 1995;122:778-788.
68. Giwercman A, Rylander L, Giwercman YL. Influence of endocrine disruptors on human male fertility. Reprod Biomed Online 2007; 15:633-642.
69. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999;59:4392-4399.
70. Gofflot F, Hars C, Illien F, Chevy F, Wolf C, Picard JJ, Roux C. Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of Hedgehog signaling. Hum Mol Genet 2003;12:1187-1198.
71. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
72. Haefely W. Benzodiazepine interactions with GABA receptors. Neurosci Lett 1984;47:201-206.
73. A ß3 subunit gene is required for normal palate development in mice. Dev Biol 2003;254:93-101.
74. Hansen JM. Oxidative stress as a mechanism of teratogenesis. Birth Defects Res C Embryo Today 2006;78:293-307.
75. Hansen JM, Harris C. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-κB pathway. Antioxid Redox Signal 2004;6:1-14.
76. Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. Medications as a source of human exposure to phthalates. Environ Health Perspect 2004; 112:751-753.
77. Helms JA, Kim CH, Hu D, Minkoff R, Thaller C, Eichele G. Sonic hedgehog participates in craniofacial morphogenesis and is down-regulated by teratogenic doses of retinoic acid. Dev Biol 1997;187:25-35.
78. Henry EC, Miller RK, Baggs RB. Direct fetal injections of diethylstilbestrol and 17b-estradiol: a method for investigating their teratogenicity. Teratology 1984;29:297-304.
79. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-881.
80. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-1614.
81. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-968.
82. Hernández-Díaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect 2009;117:185-189.
83. Hodgert Jury H, Zacharewski TR, Hammond GL. Interactions between human plasma sex hormone-binding globulin and xenobiotic ligands. J Steroid Biochem Mol Biol 2000;75:167-176.
84. Hootnick DR, Levinsohn EM, Randall PA, Packard DS Jr. Vascular dysgenesis associated with skeletal dysplasia of the lower limb. J Bone Joint Surg Am 1980;62:1123-1129.
85. Hoyme HE, Higginbottom MC, Jones KL. Vascular etiology of disruptive structural defects in monozygotic twins. Pediatrics 1981a;67:288-291.
86. Hoyme HE, Higginbottom MC, Jones KL. The vascular pathogenesis of gastroschisis: intrauterine interruption of the omphalomesenteric artery. J Pediatr 1981b;98:228-231.
87. Hoyme HE, Jones KL, Van Allen MI, Saunders BS, Benirschke K. Vascular pathogenesis of transverse limb reduction defects. J Pediatr 1982; 101:839-843.
88. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and functional aspects of testicular descent and cryptorchidism. Endocr Rev 1997;18:259-280.
89. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999;283:70-74.
90. Ishibashi M, Akazawa S, Sakamaki H, Matsumoto K, Yamasaki H, Yamaguchi Y, Goto S, Urata Y, Kondo T, Nagataki S. Oxygen-induced embryopathy and the significance of glutathione-dependent antioxidant system in the rat embryo during early organogenesis. Free Radic Biol Med 1997;22:447-454.
91. Jackson EK, Garrison JC. Renin and angiotensin. In Hardman JG, Limbird LE (eds). Goodman & Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996, 733-758.
92. Jeffery S, Edwards Y, Carter N. Distribution of CAIII in fetal and adult human tissue. Biochem Genet 1980;18:843-849.
93. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-299.
94. Jones KL. Developmental pathogenesis of defects associated with prenatal cocaine exposure: fetal vascular disruption. Clin Perinatol 1991; 18:139-146.
95. Jordan RL, Wilson JG, Schumacher HJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 1977;15:73-79.
96. Josso N, di Clemente N, Gouédard L. Anti-Müllerian hormone and its receptors. Mol Cell Endocrinol 2001;179:25-32.
97. Juchau MR, Lee QP, Fantel AG. Xenobiotic biotransformation/bioactivation in organogenesis-stage conceptual tissues: implications for embryotoxicity and teratogenesis. Drug Metab Rev 1992; 24:195-238.
98. Källén BAJ, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-261.
99. Källén BAJ, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-308.
100. Kallio H, Pastorekova S, Pastorek J, Waheed A, Sly WS, Mannisto S, Heikinheimo M, Parkkila S. Expression of carbonic anhydrases IX and XII during mouse embryonic development. BMC Dev Biol 2006;6:22.
101. Kappus H. Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem Pharmacol 1986;35:1-6.
102. Kastner P, Grondona JM, Mark M, Gansmuller A, LeMeur M, Decimo D, Vonesch JL, Dollé P, Chambon P. Genetic analysis of RXRa developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 1994;78:987-1003.
103. Kelley RI, Herman GE. Inborn errors of sterol biosynthesis. Annu Rev Genomics Hum Genet 2001;2:299-341.
104. Kester MHA, Bulduk S, Tibboel D, Meinl W, Glatt H, Falany CN, Coughtrie MWH, Bergman A, Safe SH, Kuiper GGJM et al. Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology 2000;141:1897-1900.
105. Kim KS, Torres CR Jr, Yucel S, Raimondo K, Cunha GR, Baskin LS. Induction of hypospadias in a murine model by maternal exposure to synthetic estrogens. Environ Res 2004;94:267-275.
106. Kino Y. Clinical and experimental studies of the congenital constriction band syndrome, with an emphasis on its etiology. J Bone Joint Surg Am 1975;57:636-643.
107. Kirby ML, Waldo KL. Role of neural crest in congenital heart disease. Circulation 1990;82:332-340.
108. Klip H, Verloop J, van Gool JD, Koster META, Burger CW, van Leeuwen FE. Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet 2002;359:1102-1107.
109. Klopper A. The new placental proteins. Placenta 1980;1:77-89.
110. Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science 1993;260:95-97.
111. Komuro H, Watanabe M, Matoba K, Kaneko M. Gastroschisis with omphalomesenteric artery remnant, colonic atresia and arthrogryposis multiplex congenita. Eur J Pediatr Surg 2003;13:334-336.
112. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991;206:297-300.
113. Kovacic P, Jacintho JD. Reproductive toxins: pervasive theme of oxidative stress and electron transfer. Curr Med Chem 2001;8:863-892.
114. Kovacic P, Somanathan R. Mechanism of teratogenesis: electron transfer, reactive oxygen species, and antioxidants. Birth Defects Res C Embryo Today 2006;78:308-325.
115. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002;187:1623-1630.
116. Krumlauf R. Hox genes in vertebrate development. Cell 1994;78:191-201.
117. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. J Am Med Assoc 1998;279:609-610.
118. LaBonne C, Bronner-Fraser M. Neural crest induction in Xenopus: evidence for a two-signal model. Development 1998;125:2403-2414.
119. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-2681.
120. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985; 30:145-155.
121. Lambrot R, Muczynski V, Lécureauil C, Angenard G, Coffigny H, Pairault C, Moison D, Frydman R, Habert R, Rouiller-Fabre V. Phthalates impair germ cell development in the human fetal testis in vitro without change in testosterone production. Environ Health Perspect 2009;117:32-37.
122. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT et al. Retinoic acid embryopathy. N Engl J Med 1985;313:837-841.
123. Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J 1997;11:118-124.
124. Larsen WJ. Human Embryology, 3rd edn. Philadelphia: Churchill Livingstone, 2001.
125. Lauder JM. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 1993;16:233-240.
126. 2C receptors in the mouse embryo. Int J Dev Neurosci 2000; 18:653-662.
127. Layton WM Jr, Hallesy DW. Deformity of forelimb in rats: association with high doses of acetazolamide. Science 1965;149:306-308.
128. Lee H, Choi BH. Density and distribution of excitatory amino acid receptors in the developing human fetal brain: a quantitative autoradiographic study. Exp Neurol 1992;118:284-290.
129. Li D, Pickell L, Liu Y, Wu Q, Cohn JS, Rozen R. Maternal methylenetetrahydrofolate reductase deficiency and low dietary folate lead to adverse reproductive outcomes and congenital heart defects in mice. Am J Clin Nutr 2005;82:188-195.
130. Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol 2004;70:534-536.
131. Liu L, Wells PG. In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets of chemical teratogenesis. Toxicol Appl Pharmacol 1994;125:247-255.
132. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002;100:465-473.
133. Lohnes D, Mark M, Mendelsohn C, Dollé P, Dierich A, Gorry P, Gansmuller A, Chambon P. Function of the retinoic acid receptors (RARs) during development (I). Craniofacial and skeletal abnormalities in RAR double mutants. Development 1994;120:2723-2748.
134. Lönnerholm G, Wistrand PJ. Carbonic anhydrase in the human fetal kidney. Pediatr Res 1983;17:390-397.
135. Los FJ, Brandenburg H, Niermeijer MF. Vascular disruptive syndromes after exposure to misoprostol or chorionic villus sampling. Lancet 1999;353:843-844.
136. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-2683.
137. Louw JH, Barnard CN. Congenital intestinal atresia: observations on its origin. Lancet 1955;266:1065-1067.
138. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev 2001; doi:10.1002/14651858.CD001056.
139. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:29-38.
140. Madshus IH. Regulation of intracellular pH in eukaryotic cells. Biochem J 1988;250:1-8.
141. Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:595-781.
142. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216.
143. Martin OV, Shialis T, Lester JN, Scrimshaw MD, Boobis AR, Voulvoulis N. Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. Environ Health Perspect 2008;116:149-157.
144. McLachlan JA. Rodent models for perinatal exposure to diethylstilbestrol and their relation to human disease in the male. In Herbst AL, Bern HA (eds). Developmental Effects of Diethylstilbestrol (DES) in Pregnancy. New York, NY: Thieme-Stratton, 1981, 148-157.
145. McMahon DR, Kramer SA, Husmann DA. Antiandrogen induced cryptorchidism in the pig is associated with failed gubernacular regression and epididymal malformations. J Urol 1995; 154:553-557.
146. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997;57:3697-3707.
147. Meijer WM, de Walle HEK, Kerstjens-Frederikse WS, de Jong-van den Berg LTW. Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists. Reprod Toxicol 2005;20:203-207.
148. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-1172.
149. Menegola E, Di Renzo F, Broccia ML, Prudenziati M, Minucci S, Massa V, Giavini E. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol 2005;74:392-398.
150. Metzler M. The metabolism of diethylstilbestrol. CRC Crit Rev Biochem 1981;10:171-212.
151. Miller RK, Heckmann ME, McKenzie RC. Diethylstilbestrol: placental transfer, metabolism, covalent binding and fetal distribution in the Wistar rat. J Pharmacol Exp Ther 1982;220:358-365.
152. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-151.
153. Mittelbronn M, Beschorner R, Schittenhelm J, Capper D, Goeppert B, Meyermann R, Meyer-Wittkopf M, Mackensen-Haen S. Multiple thromboembolic events in fetofetal transfusion syndrome in triplets contributing to the understanding of pathogenesis of hydranencephaly in combination with polymicrogyria. Hum Pathol 2006;37:1503-1507.
154. Moiseiwitsch JRD, Lauder JM. Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci USA 1995;92:7182-7186.
155. 12 status and risk of neural tube defects in a population with high neural tube defect prevalence and no folic acid fortification. Pediatrics 2009;123:917-923.
156. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-540.
157. Morini F, Cozzi DA, Ilari M, Casati A, Cozzi F. Pattern of cardiovascular anomalies associated with esophageal atresia: support for a caudal pharyngeal arch neurocristopathy. Pediatr Res 2001;50:565-568.
158. Morriss-Kay G. Retinoic acid and craniofacial development: molecules and morphogenesis. Bioessays 1993;15:9-15.
159. Myers MF, Li S, Correa-Villaseñor A, Li Z, Moore CA, Hong SX, Berry RJ. Folic acid supplementation and risk for imperforate anus in China. Am J Epidemiol 2001;154:1051-1056.
160. Mylchreest E, Sar M, Wallace DG, Foster PMD. Fetal testosterone insufficiency and abnormal proliferation of Leydig cells and gonocytes in rats exposed to di(n-butyl) phthalate. Reprod Toxicol 2002;16:19-28.
161. Nakagawa S, Takeichi M. Neural crest emigration from the neural tube depends on regulated cadherin expression. Development 1998; 125:2963-2971.
162. 2B receptors in mice leads to abnormal cardiac structure and function. Circulation 2001;103:2973-2979.
163. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. Br Med J 2001;322:266-270.
164. Nishibatake M, Kirby ML, Van Mierop LH. Pathogenesis of persistent truncus arteriosus and dextroposed aorta in the chick embryo after neural crest ablation. Circulation 1987;75:255-264.
165. Norstedt Wikner B, Stiller CO, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations Pharmacoepidemiol. Drug Saf 2007;16:1203-1210.
166. Ofori B, Oraichi D, Blais L, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol 2006;77:268-279.
167. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, Sørensen HT. Drug use in first pregnancy and lactation: a population-based survey among Danish women. Eur J Clin Pharmacol 1999;55:139-144.
168. Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000;107:519-523.
169. Ornoy A. Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy. Reprod Toxicol 2007; 24:31-41.
170. Ornoy A, Arnon J, Shechtman S, Moerman L, Lukashova I. Is benzodiazepine use during pregnancy really teratogenic? Reprod Toxicol 1998;12:511-515.
171. Otten C, Migliazza L, Xia H, Rodriguez JI, Diez-Pardo JA, Tovar JA. Neural crest-derived defects in experimental esophageal atresia. Pediatr Res 2000;47:178-183.
172. Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, Gray LE Jr. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol Sci 2000;58:339-349.
173. Parle-McDermott A, Kirke PN, Mills JL, Molloy AM, Cox C, O'Leary VB, Pangilinan F, Conley M, Cleary L, Brody LC et al. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet 2006;14:768-772.
174. Parman T, Wells PG. Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice. FASEB J 2002;16:1001-1009.
175. Parman T, Chen G, Wells PG. Free radical intermediates of phenytoin and related teratogens. J Biol Chem 1998;273:25079-25088.
176. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A 2008;146:2701-2705.
177. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-36741.
178. Physicians' Desk Reference, 63rd edn. Montvale, NJ: Thomson Reuters, 2009.
179. Pollard I. Neuropharmacology of drugs and alcohol in mother and fetus. Semin Fetal Neonatal Med 2007;12:106-113.
180. Pryde PG, Sedman AB, Nugent CE, Barr M. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993;3:1575-1582.
181. Puvabanditsin S, Garrow E, Augustin G, Titapiwatanakul R, Kuniyoshi KM. Poland-Möbius syndrome and cocaine abuse: a relook at vascular etiology. Pediatr Neurol 2005;32:285-287.
182. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11:2069-2083.
183. 12 and the risk of neural tube defects in a folic-acid-fortified population. Epidemiology 2007;18:362-366.
184. Raymond GV. Teratogen update: ergot and ergotamine. Teratology 1995; 51:344-347.
185. Rider CV, Furr J, Wilson VS, Gray LE Jr. A mixture of seven antiandrogens induces reproductive malformations in rats. Int J Androl 2008;31:249-262.
186. Rosenberg L, Mitchell AA, Parsells JL, Pashayan H, Louik C, Shapiro S. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983;309:1282-1285.
187. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996;93:15227-15232.
188. Ryu S, Kohen R, Samuni A, Ornoy A. Nitroxide radicals protect cultured rat embryos and yolk sacs from diabetic-induced damage. Birth Defects Res A Clin Mol Teratol 2007;79:604-611.
189. Sahambi SK, Hales BF. Exposure to 5-bromo-2'-deoxyuridine induces oxidative stress and activator protein-1 DNA binding activity in the embryo. Birth Defects Res A Clin Mol Teratol 2006;76:580-591.
190. Sari Y, Zhou FC. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003;21:417-424.
191. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment Options and Risk Assessment, 2nd edn. London: Academic Press, 2007.
192. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr 2005;81:1218S-1222S.
193. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, van Gompel P, Lesage AS, de Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
194. Schütz S, Le Moullec JM, Corvol P, Gasc JM. Early expression of all the components of the renin-angiotensin-system in human development. Am J Pathol 1996;149:2067-2079.
195. Schwarz EB, Postlethwaite DA, Hung YY, Armstrong MA. Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women. Ann Intern Med 2007; 147:370-376.
196. Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet 1994; 27:337-344.
197. Scott WJ, Duggan CA, Schreiner CM, Collins MD. Reduction of embryonic intracellular pH: a potential mechanism of acetazolamide-induced limb malformations. Toxicol Appl Pharmacol 1990;103:238-254.
198. Shalev SA, Hall JG. Poland anomaly: report of an unusual family. Am J Med Genet A 2003;118:180-183.
199. Sharpe RM. Pathways of endocrine disruption during male sexual differentiation and masculinization. Best Pract Res Clin Endocrinol Metab 2006;20:91-110.
200. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995;59:536-545.
201. Sheehan DM, Young M. Diethylstilbestrol and estradiol binding to serum albumin and pregnancy plasma of rat and human. Endocrinology 1979; 104:1442-1446.
202. Shepard TH, Lemire RJ. Catalog of Teratogenic Agents, 12th edn. Baltimore: The John Hopkins University Press, 2007.
203. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;96:451-456.
204. Shuey DL, Sadler TW, Lauder JM. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 1992;46:367-378.
205. Shuey DL, Sadler TW, Tamir H, Lauder JM. Serotonin and morphogenesis. Transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol 1993;187:75-85.
206. Slikker W Jr, Hill DE, Young JF. Comparison of the transplacental pharmacokinetics of 17b-estradiol and diethylstilbestrol in the subhuman primate. J Pharmacol Exp Ther 1982;221:173-182.
207. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995;64:375-401.
208. Smets K, Zecic A, Willems J. Ergotamine as a possible cause of Möbius sequence: additional clinical observation. J Child Neurol 2004;19:398.
209. Spranger J, Benirschke K, Hall JG, Lenz W, Lowry RB, Opitz JM, Pinsky L, Schwarzacher HG, Smith DW. Errors of morphogenesis: concepts and terms. Recommendations of an international working group. J Pediatr 1982;100:160-165.
210. Stanfield KM, Bell RR, Lisowski AR, English ML, Saldeen SS, Khan KNM. Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res A Clin Mol Teratol 2003;67:54-58.
211. Steegers-Theunissen RP, Boers GH, Blom HJ, Nijhuis JG, Thomas CMG, Borm GF, Eskes TK. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995;172:1436-1441.
212. Stoller JZ, Epstein JA. Cardiac neural crest. Semin Cell Dev Biol 2005; 16:704-715.
213. Storgaard L, Bonde JP, Olsen J. Male reproductive disorders in humans and prenatal indicators of estrogen exposure. A review of published epidemiological studies. Reprod Toxicol 2006;21:4-15.
214. Strachan LR, Condic ML. Neural crest motility on fibronectin is regulated by integrin activation. Exp Cell Res 2008;314:441-452.
215. Streck RD, Kumpf SW, Ozolinš TRS, Stedman DB. Rat embryos express transcripts for cyclooxygenase-1 and carbonic anhydrase-4, but not for cyclooxygenase-2, during organogenesis. Birth Defects Res B Dev Reprod Toxicol 2003;68:57-69.
216. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 2005;113:1056-1061.
217. TERIS: Teratogen Information System. Available at: http://depts. washington.edu/terisweb/teris. Retrieved April, 29 2009.
218. Thiersch JB. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A.) administered by the oral route. Am J Obstet Gynecol 1952;63:1298-1304.
219. 67. J Neurochem 1992; 58:618-627.
220. Trocino RA, Akazawa S, Ishibashi M, Matsumoto K, Matsuo H, Yamamoto H, Goto S, Urata Y, Kondo T, Nagataki S. Significance of glutathione depletion and oxidative stress in early embryogenesis in glucose-induced rat embryo culture. Diabetes 1995;44:992-998.
221. Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 1991;69:149-156.
222. U.S. Food and Drug Administration. Code of Federal Regulations, Title 21, Vol. 4. Washington, DC: U.S. Government Printing Office, 2003, 21-32.
223. van Aerts LAGJM, Klaasboer HH, Postma NS, Pertijs JCLM, Copius Peereboom JHJ, Eskes TKAB, Noordhoek J. Stereospecific in vitro embryotoxicity of L-homocysteine in pre-and post-implantation rodent embryos. Toxicol in Vitro 1993;7:743-749.
224. Van Allen MI. Structural anomalies resulting from vascular disruption. Pediatr Clin North Am 1992;39:255-277.
225. van der Linden IJM, den Heijer M, Afman LA, Gellekink H, Vermeulen SHHM, Kluijtmans LAJ, Blom HJ. The methionine synthase reductase 66A.G polymorphism is a maternal risk factor for spina bifida. J Mol Med 2006;84:1047-1054.
226. van der Put NMJ, van Straaten HWM, Trijbels FJM, Blom HJ. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med 2001;226:243-270.
227. van Rooij IALM, Vermeij-Keers C, Kluijtmans LAJ, Ocké MC, Zielhuis GA, Goorhuis-Brouwer SM, van der Biezen JJ, Kuijpers-Jagtman AM, Steegers-Theunissen RPM. Does the interaction between maternal folate intake and the methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or without cleft palate? Am J Epidemiol 2003;157:583-591.
228. van Rooij IALM, Ocké MC, Straatman H, Zielhuis GA, Merkus HMWM, Steegers-Theunissen RPM. Periconceptional folate intake by supplement and food reduces the risk of nonsyndromic cleft lip with or without cleft palate. Prev Med 2004;39:689-694.
229. Vanaerts LAGJM, Blom HJ, Deabreu RA, Trijbels FJM, Eskes TKAB, Copius Peereboom-Stegeman JHJ, Noordhoek J. Prevention of neural tube defects by and toxicity of L-homocysteine in cultured postimplantation rat embryos. Teratology 1994;50:348-360.
230. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
231. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VFA, Sugayama SMM, Albano L, Llerena JC Jr, Almeida JCC, Duarte A et al. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. Am J Med Genet 2000;95:302-306.
232. Varju P, Katarova Z, Madarász E, Szabó G. GABA signalling during development: new data and old questions. Cell Tissue Res 2001; 305:239-246.
233. Waldo K, Miyagawa-Tomita S, Kumiski D, Kirby ML. Cardiac neural crest cells provide new insight into septation of the cardiac outflow tract: aortic sac to ventricular septal closure. Dev Biol 1998;196:129-144.
234. Waxman JS, Yelon D. Increased Hox activity mimics the teratogenic effects of excess retinoic acid signaling. Dev Dyn 2009; 238:1207-1213.
235. Wellfelt K, Sköld AC, Wallin A, Danielsson BR. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod Toxicol 1999;13:93-101.
236. Wells PG, Winn LM. Biochemical toxicology of chemical teratogenesis. Crit Rev Biochem Mol Biol 1996;31:1-40.
237. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn LM. Oxidative damage in chemical teratogenesis. Mutat Res 1997; 396:65-78.
238. Wells PG, Bhuller Y, Chen CS, Jeng W, Kasapinovic S, Kennedy JC, Kim PM, Laposa RR, McCallum GP, Nicol CJ et al. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol Appl Pharmacol 2005;207:S354-S366.
239. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. Am J Epidemiol 1999; 150:675-682.
240. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002; 155:26-31.
241. Werler MM, Sheehan JE, Hayes C, Mitchell AA, Mulliken JB. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol 2004;70:389-395.
242. Wilcox AJ, Lie RT, Solvoll K, Taylor J, McConnaughey DR, Åbyholm F, Vindenes H, Vollset SE, Drevon CA. Folic acid supplements and risk of facial clefts: national population based case-control study. Br Med J 2007;334:464.
243. Wilson JG, Roth CB, Warkany J. An analysis of the syndrome of malformations induced by maternal vitamin A deficiency. Effects of restoration of vitamin A at various times during gestation. Am J Anat 1953;92:189-217.
244. Winn LM, Wells PG. Free radical-mediated mechanisms of anti-convulsant teratogenicity. Eur J Neurol 1995;2:5-29.
245. Winn LM, Wells PG. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic Biol Med 1997;22:607-621.
246. Winn LM, Wells PG. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic Biol Med 1999; 26:266-274.
247. Wong BY, Coulter DA, Choi DW, Prince DA. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 1988; 85:261-266.
248. Yan J, Hales BF. Depletion of glutathione induces 4-hydroxynonenal protein adducts and hydroxyurea teratogenicity in the organogenesis stage mouse embryo. J Pharmacol Exp Ther 2006; 319:613-621.
249. Yanagisawa H, Yanagisawa M, Kapur RP, Richardson JA, Williams SC, Clouthier DE, de Wit D, Emoto N, Hammer RE. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 1998;125:825-836.
250. Yavarone MS, Shuey DL, Sadler TW, Lauder JM. Serotonin uptake in the ectoplacental cone and placenta of the mouse. Placenta 1993a; 14:149-161.
251. Yavarone MS, Shuey DL, Tamir H, Sadler TW, Lauder JM. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 1993b; 47:573-584.
252. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179.
253. Yu WK, Wells PG. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice. Toxicol Appl Pharmacol 1995; 131:1-12.
254. Zaken V, Kohen R, Ornoy A. The development of antioxidant defense mechanism in young rat embryos in vivo and in vitro. Early Pregnancy 2000;4:110-123.
255. Zhang HY, Luo GA, Liang QL, Wang Y, Yang HH, Wang YM, Zheng XY, Song XM, Chen G, Zhang T et al. Neural tube defects and disturbed maternal folate-and homocysteine-mediated one-carbon metabolism. Exp Neurol 2008;212:515-521.